Advances in islet transplantation have encouraged efforts to create alternative insulin-secreting cells that overcome limitations associated with current therapies. We have recently demonstrated durable correction of murine and porcine diabetes by syngeneic and autologous implantation, respectively, of primary hepatocytes non-virally modified with a glucose-responsive promoter-regulated insulin transgene. As surgical procurement of hepatocytes may be clinically unappealing, we here describe primary bone marrow-derived mesenchymal stromal cells (BMMSC) as alternative insulinsecreting bioimplants. BMMSC are abundant and less invasively procured for clinical autologous transplantation. Electroporation achieved high transgene transfection efficiencies in human BMMSC (HBMMSC) and porcine BMMSC (PBMMSC). We transcriptomically identified an HBMMSC glucose-responsive promoter, EGR1. This endogenously active promoter drove rapid glucose-induced transgene secretions in BMMSC with near-physiological characteristics during static and kinetic induction assays simulating normal human islets. Preparatory to preclinical transplantation, PBMMSC transfected with the circular insulin transgene vector or stably integrated with the linearized vector were evaluated by intrahepatic or intraperitoneal xenotransplantation in streptozotocin-diabetic and non-diabetic NOD-SCID mice. Hyperglycemia, glucose tolerance and body weight were corrected in a dose-responsive manner. Hypoglycemia was not observed even in identically implanted non-diabetic mice. These results establish human EGR1 promoter-insulin construct-modified BMMSC as safe and efficient insulin-secreting bioimplants for diabetes treatment.
Introduction
Promising outcomes of allogeneic islet transplantation in insulin-dependent diabetics have revived interest in cell therapy of diabetes mellitus. However, elation at the initial success has been tempered by progressive loss of function of the grafted islets in most recipients treated by the Edmonton protocol. 1 Causes for the loss of islet function, though unclear, are probably multifactorial, that is, chronic alloimmune rejection, recurrent autoimmune destruction of b-cells and increased apoptosis of the islets coupled with failure of compensatory replication as immunosuppression may impede the differentiation of islet progenitors. 2, 3 Although islet transplantation demonstrated clear therapeutic efficacy and was therefore a true advance in diabetes treatment, it is important to reconsider if the adverse effects of lifelong immunosuppression outweigh the relatively short-term gains of islet transplantation. Moreover, only a miniscule number of all diabetics could benefit due to the shortage of useful donor pancreata and the fact that replicating the success of the Edmonton protocol would be possible only in a few specialized centers.
Active efforts at obviating the inherent limitations of islet transplantation can be broadly categorized into two major approaches: (1) protecting, regenerating or increasing endogenous b-cell mass; and (2) developing new, and possibly inexhaustible, sources of transplantable insulin-expressing cells. The latter strategy relies on generating b-or b-like cells by induced replication, differentiation, forced expression of transcription factors or direct in vivo reprogramming; or modifying non-b cells to function as surrogate sources of insulin secretion. Although generating b-cells from embryonic, adult stem/progenitor cells or induced pluripotent cells, and from terminally differentiated non b-cells (for example, liver cells) is an important goal, it is uncertain if clinically meaningful numbers of insulin-secreting cells can be generated with current protocols. Moreover, whether these cells will survive chronic allo-rejection and/or recurrent autoimmune destruction are questions yet to be addressed.
An alternate approach for developing insulin-secreting cells simply transfers a proinsulin cDNA expression vector into non-b-cells. A major criticism of this stratagem has been the uncoupling of transcription/ translation from secretion of transgenic insulin in response to changing blood glucose concentrations. Consequently, hypoglycemia is a major concern as most investigators currently rely on glucose-dependent transcriptional regulation of transgenic insulin expression.
We have previously demonstrated ex vivo electrotransfer of non-viral insulin expression vectors, regulated by strong constitutive and glucose-responsive promoters, in primary adult murine and porcine hepatocytes. Rapid, near-physiological glucose-regulated transgenic proinsulin transcription and insulin secretion was achieved in vitro. Transplantation of plasmid-electroporated syngeneic primary hepatocytes corrected murine streptozotocin (STZ)-induced diabetes. 4 Similarly, intrahepatic (IH) implantation of autologous primary hepatocytes in diabetic pigs showed durable (X47 weeks) correction of hyperglycemia, glucose intolerance, dyslipidemia and other metabolic abnormalities, which correlated significantly with the number of hepatocytes implanted. 5 Importantly, we observed no hypoglycemia, regardless of feeding behavior, that is, the 'nibbling' behavior of mice and 'humanized' mealtime feeding of pigs, and even under fasting conditions in both animal models.
As surgical procurement of hepatocytes may not be clinically appealing, we turned to primary bone marrowderived mesenchymal stromal cells (BMMSC) as an alternative for developing insulin-secreting bioimplants. BMMSC are readily procured in abundance, easily expandable to clinically meaningful numbers for autologous transplantation and are already used in clinical trials for a range of diseases. 6 We describe here the feasibility of using these cells as glucose-regulatable surrogate b-cells for the treatment of insulin-deficient diabetes.
Results

Non-viral gene transfer in human and porcine BMMSC
We achieved high efficiency of electrogenetransfer in primary human and porcine BMMSC (PBMMSC) using NC solution (see Materials and methods). Electroporation of 2 Â 10 6 human BMMSC (HBMMSC) with a single pulse of 150 V for 15 ms in a 2 mm cuvette (field strength: 750 V cm À1 ) was associated with high transfection efficiency (83.21±2.65%), good cell viability (87.2±2.2%) and highest secretion of the reporter, secreted alkaline phosphatase (SEAP), (149.4±9.0 ng SEAP per ml) compared with other pulse settings. We achieved comparable outcomes in electroporated PBMMSC (94.56±1.98% transfection efficiency, 87.7 ± 3.0% cell viability and 148.5±24.7 ng SEAP per ml), albeit with different pulse settings, that is, 200 V for 10 ms (field strength: 1000 V cm À1 ) (Figures 1a-c ). These levels of transfection efficiency and cell viability were comparable with the performance of a proprietary solution. 7 The foregoing results demonstrated highly efficient transfection in primary adult HBMMSC and PBMMSC using a nonviral system.
No evidence of genomic integration of electroporated circular plasmid
To address the concern that electroporation may cause genomic integration of transfected DNA, we designed two pairs of PCR primers to amplify two separate regions of the electroporated plasmid using semiquantitative PCR. Figure 1d shows discrete amplicons generated from genomic DNA isolated from PBMMSC clone 5 that was stably integrated with linearized pTopo3EGR1chINS (C t values for primer set 1 ¼ 28.19716 ± 0.15090; for primer set 2 ¼ 29.18261±0.16150), while there was no detectable amplification from genomic DNA of PBMMSC electroporated with the same plasmid in circular form. This is consistent with published reports that genomic integration of naked plasmid DNA (especially in circular form) is extremely rare. A recent report indicated that integration events following plasmid electroporation were at least three orders of magnitude less frequent than the spontaneous rate of genome mutation. 8 
Selection of endogenous HBMMSC glucoseresponsive promoter
We used whole genome expression arrays to screen for endogenous promoters capable of driving rapid quasiphysiological glucose-regulated insulin expression in primary BMMSC. In order to enrich for transcripts that were rapidly induced and de-induced in high and low glucose concentrations, respectively, we processed cells for total RNA within minutes of exposure to the glucose stimulant. Four glucose-inducible transcripts, namely, early growth response-1 and -3 (EGR1 and EGR3, respectively), v-fos murine osteosarcoma viral oncogene homolog (FOS) and a cDNA clone of unknown function, UniGene ID Hs.671830 were selected for further evaluation (Table 1) . Semiquantitative reverse transcription (RT)-PCR showed comparable levels of induction as genome-wide transcriptome data. EGR1, a zinc-finger transcription factor, was particularly attractive because it showed a near-physiological response to glucose stimulus.
There are similarities between our data and earlier data of Josefsen et al. 9 of glucose-induced EGR1 mRNA in b-cells. These authors reported maximum glucosestimulated EGR1 expression within 30 min and a return to baseline 3 h after stimulation. As EGR1 binds to its own promoter, the resulting feed-forward regulatory effect likely explains the slower decline in transcript levels during the de-induction phase of this study. In contrast, FOS transcription did not show clear glucose responsiveness in the semiquantitative RT-PCR analysis, while expression levels of Hs.671830 were too low to confidently predict the practical use of its promoter for transgenic insulin expression. Supplementary Table S1 lists glucose-responsive transcripts that were upregulated 41.5-fold and 43-fold at 15 and 30 min, respectively, after exposure to high glucose.
Ten minutes after exposure to 20 mM glucose, SEAP activity from modified PBMMSC increased 2.3±0.4-fold above the basal level, defined as SEAP activity in 3 mM glucose-medium in which modified PBMMSC had been cultured for 48 h (Figure 2b ). Expression from EGR1-SEAP further increased to 7.0±0.7-fold above baseline 30 min after high glucose induction. Upon medium change from 20 to 3 mM glucose, SEAP activity ceased increasing and instead decreased over time. In contrast, SEAP activity expressed by PBMMSC, modified with a control SV40 promoter-SEAP construct, was time-dependent but glucose-independent, as SEAP levels continued to increase even after withdrawal of high glucose. Concordant with glucose-induced SEAP activity, relative SEAP transcript levels from EGR1-SEAP-modified cells were 10.7±1.0-fold higher after 30 min in 20 mM glucose than in 3 mM glucose ( Figure 2c ) and declined to almost basal levels 90 min after returning to 3 mM glucose (1.68 ± 0.64-fold). In contrast, transcripts expressed from SV40-SEAP remained unchanged throughout.
Full-length human EGR1 promoter conferred optimal glucose inducibility. As multiple regulatory DNA motifs are embedded within the EGR1 promoter sequence, various truncated variants of the full-length promoter were constructed to ascertain whether some or all motifs were required for optimal glucose-stimulated Original magnification Â 100 for both images. (d) Semiquantitative PCR (50 cycles) was performed on genomic DNA isolated from (i) unmodified (that is, untransfected) PBMMSC as negative control, (ii) pTopo3EGR1chINS-stably modified PBMMSC clone 5 generated by electroporating the linearized plasmid; and (iii) PBMMSC electroporated with the same plasmid in circular form. To ensure no contamination of genomic DNA by circular plasmid DNA, electroporated cells were cultured for several cell doublings before isolation of genomic DNA. Two pairs of PCR primers amplifying two different regions of the plasmid were tested, that is, primers set 1: between EGR1 promoter and human (pro)insulin cDNA (165 bp); and primers set 2: within the neomycin resistance gene (117 bp). Amplicons, if present in each genomic DNA preparation, would be visualized in the left and right lanes of each bracket with primer sets 1 and 2, respectively. Note that no amplification was observed from genomic DNA prepared from PBMMSC electroporated with circular plasmid regardless of the amount of input DNA used (that is, 5 or 50 ng).
Bone marrow-derived insulin bioimplants NKF Chen et al insulin expression in PBMMSC (Figure 2a ). Full-length EGR1 promoter mediated highest glucose-responsive increase in human insulin secretion ( Figure 2d ). The threshold for stimulating insulin secretion was 5 mM glucose (P ¼ 0.0145 cf. 2.5 mM glucose, P ¼ 0.0037 cf. 10 mM glucose). EGR1 promoter segment A did not respond to glucose, whereas EGR1 promoter segments B and C had higher glucose thresholds for insulin secretion (that is, 10-20 mM). As all three promoter segments contained at least one putative carbohydrate-response element, it is possible that the longer full-length promoter provided a conformationally more stable structure for binding transcription factors. All insulin secretion from PBMMSC was assessed by measuring insulin concentrations in conditioned media using a human insulin radioimmunoassay that was o0.2% crossreactive with human proinsulin. The same samples were also analyzed for human proinsulin using an assay whose sensitivity for proinsulin was 2 pM and had o0.1% crossreactivity with insulin. Absence of detectable proinsulin in all experiments indicates that PBMMSC efficiently processed proinsulin to insulin.
Human EGR1 promoter was not activated by physiological concentrations of insulin. As EGR1 expression is reportedly stimulated by insulin, 10 it was possible that a construct in which the EGR1 promoter drives insulin expression could have undesirable feed-forward characteristics and could cause hypoglycemia in vivo. However, C-peptide secretion did not increase significantly when the transfected cells were incubated with physiological concentrations of insulin added in recombinant form (human reference range: 1-30 mU ml À1 or 6-180 pM) (Figure 2e ). Nonetheless, in agreement with reports of stimulated EGR1 expression by nanomolar concentrations of insulin, we also detected significant increases in C-peptide secretion when cells were incubated with recombinant insulin in concentrations that were more than 25-fold higher than the physiological range in humans, that is, 5 nM. These insulin concentrations have never been reported, even in patients with pathological hyperinsulinemia.
11
Human EGR1 promoter was not glucocorticoid activated. EGR1 expression is also reportedly stimulated by a range of stressful conditions. We thus examined the effect of a potent glucocorticoid, dexamethasone, on expression from the EGR1-insulin construct (Figure 2f ). In contrast to recent reports of dexamethasone-regulated EGR1-directed gene transcription, 12 we observed no effect of dexamethasone. This discrepancy may be due to differences in glucocorticoid concentrations that we and other investigators used. We showed that 2.5-20 nM dexamethasone, that is, equivalent to 95-760 nM cortisol (human reference range for serum-free cortisol: 5-53 nM) did not significantly increase insulin secretion by modified PBMMSC.
Kinetics of glucose-induced human insulin secretion from modified primary PBMMSC. We characterized the kinetics of glucose-inducible insulin secretion by PBMMSC electroporated with a human insulin construct having either the full-length EGR1 promoter (Figure 3a) or the EGR1(B) promoter segment (Figure 3b ) in perifusion experiments, and co-electroporated with SV40-pSEAP as control. To simulate physiological postprandial glucose excursions in vivo, glucose concentrations during perifusion were designed to increase and decrease gradually. Human insulin in the perifusate collected from EGR1 full-length promoter-modified cells increased steadily concurrently with the increase in glucose concentration. In contrast, neither the insulin concentration in the perifusate of EGR1(B)-modified cells nor did SEAP activity levels in both perifusates increase in tandem with rising glucose concentrations. Insulin levels also declined gradually when the glucose concentration perifusing the cells was progressively lowered. Insulin secretion did not return to the basal level even after 120 min in reduced glucose concentration (6.3 mM) probably because this was still above the threshold for glucose-induced insulin secretion, that is, 5 mM. Taken together, these results indicated that the human EGR1 promoter was glucose sensitive while not having characteristics of potentially inappropriate insulin secretion.
Stably modified PBMMSC secreted less human insulin than circular plasmid-electroporated PBMMSC Ten insulin-expressing stable clones were generated by electroporation of linearized pTopo3EGR1chINS encoding a neomycin/kanamycin resistance gene. These clones were tested for glucose-inducible insulin secretion Lower levels of insulin secretion in stably modified cells was likely due, in part, to the known low copy number of integrated transgenes. This explanation appears plausible given that electroporation is capable of delivering thousands of DNA molecules into nuclei. 13 Transgene (c) HBMMSC co-transfected with either EGR1-SEAP and CMV-EGFP or SV40-SEAP and CMV-EGFP were cultured in 3 mM glucose for 48 h before exposure to 20 mM glucose for the indicated durations. Cells were then lysed for total RNA isolation (2 Â 10 5 cells per plate, n ¼ 3 for EGR1-SEAP and n ¼ 2 for SV40-SEAP at each time point) and processed for semiquantitative RT-PCR of SEAP mRNA (assayed in triplicate). Note that SEAP transcripts expressed from the EGR1 promoter increased 1.22 ± 0.16-fold within 5 min of exposure to 20 mM glucose, whereas SEAP and EGFP transcripts from SV40-SEAP and CMV-EGFP did not increase throughout the experiment. (CMV-EGFP expression served as a control for transfection efficiency). (d-f) Glucose inducibility of EGR1 promoter segments. The reference construct that served as comparator in these experiments was the human metallothionein IIA promoter in p3MTchINS, which drives insulin expression in hepatocytes. 5, 6 pEGFP served as negative control. (d) PBMMSC electroporated with the aforementioned plasmid constructs (5 mg DNA/ 2 Â 10 6 cells) were cultured in DMEM with different glucose concentrations for 30 min, after which the culture medium was aspirated for human insulin and human proinsulin radioimmunoassays (1.5 Â 10 5 cells per well, three wells for each glucose concentration). Human proinsulin levels were below the sensitivity of detection (2 pM) of the radioimmunoassay kit used which had o0.1% crossreactivity with human insulin (all radioimmunoassay kits were from Linco Research). (e) PBMMSC transfected as described in panel (d) were cultured for 60 min in 5 mM glucose DMEM, supplemented with cell culture grade recombinant insulin at the concentrations indicated. Culture medium was assayed for human C-peptide using a radioimmunoassay that was not crossreactive with either native or recombinant human insulin. Note the significant induction with 5000 pM insulin (Po0.0001 cf. 500 pM insulin for EGR1(full), EGR1(A) and EGR1(C); P ¼ 0.6063 cf. 500 pM insulin for EGR1(B)). (f) Modified PBMMSC were treated with dexamethasone at the concentrations indicated and incubated for 60 min in 5 mM glucose DMEM. The culture medium was then assayed for human insulin. All data are presented as mean ± s.e.m.
Bone marrow-derived insulin bioimplants NKF Chen et al expression has been shown to correlate with copy number. 14 Another possible reason for lower insulin production was integration of the transgene into genomic regions that were less accessible to transcription factors that drive insulin expression. However, we consider this to be less probable because genomic integration in mitotic cells usually occurs in transcriptionally active euchromatin. 15 
Xenogeneic implantation of insulin-secreting primary PBMMSC into NOD-SCID mice
The performance of modified primary PBMMSC in vivo was evaluated by xenogeneic implantation into nondiabetic and STZ-diabetic NOD-SCID mice. Implantation of the modified cells in non-diabetic mice served to assess the risk of induced hypoglycemia in the event of glucose-independent insulin expression. See Supplementary Table S2 for an overview of the experimental design.
Streptozotocin-induced diabetes in NOD-SCID mice. Diabetes was induced with three consecutive daily intraperitoneal (IP) injections of 100 mg STZ/kg body weight. In this study, mice were considered diabetic when blood glucose concentrations were consistently X19.3 mM (5 s.d.'s above the mean blood glucose of all mice before the experiment commenced).
Efficacy of insulin-secreting PBMMSC in vivo: intrahepatic xenotransplantation. In light of our previous work on hepatocytes, 4, 5 we first implanted modified PBMMSC into the liver parenchyma by direct interstitial injection (IH group). Different cell numbers, that is, 2 and Figure 3 Kinetics of glucose-induced human insulin secretion by PBMMSC. One Â 10 6 PBMMSC were co-electroporated with pSV40-SEAP and either (a) human insulin construct having the full-length EGR1 promoter (EGR1full-insulin) or (b) human insulin construct having the EGR1(B) promoter (nucleotides 215-424 of the full-length promoter) (EGR1(B)-insulin). Continuous perifusion (1 ml min À1 ) at 37 1C with DMEM medium was performed 48 h after culture in 3 mM glucose, first with a gradient of increasing glucose concentration over 90 min, followed by gradually decreasing glucose concentration over 120 min. Perifusate fractions were collected every 5 min throughout each perifusion experiment and assayed for glucose concentrations (Elite glucometer, Bayer HealthCare, Mishawaka, IN, USA), human insulin (Ultrasensitive human insulin radioimmunoassay kit, Linco Research) and SEAP activity (SEAP kit, Clontech, Mountain View, CA, USA). All assays were performed in duplicate. Insets in both panels showed that SEAP activity levels were independent of ambient glucose concentrations throughout. Shown are data of two experiments.
Bone marrow-derived insulin bioimplants NKF Chen et al 5 Â 10 6 cells were tested to determine if therapeutic efficacy was cell dose-dependent. Three days after implantation of 5 Â 10 6 plasmid-electroporated PBMMSC, blood glucose levels of treated diabetic mice were normalized (P ¼ 0.3236 cf. non-diabetic mice) (Figure 5a ). Implantation of 2 Â 10 6 cells had no such effect (P ¼ 0.0005 cf. non-diabetic mice). However, both cell doses significantly reduced hyperglycemia (Po0.0001 for both, cf. untreated diabetic mice). Simultaneously, human insulin was clearly detected in the plasma of diabetic mice implanted with either 2 or 5 Â 10 6 cells (96.84 ± 27.75 and 306.47 ± 33.53 pM, respectively) (Figure 5b ). Glucose tolerance also improved during the first post-implantation week (P ¼ 0.0008 and 0.1058 for 2 and 5 Â 10 6 cells, respectively, cf. the control non-diabetic mice; P ¼ 0.0015 and o0.0001 for 2 and 5 Â 10 6 cells, respectively, cf. untreated diabetic mice) (Figure 5c ). Interestingly, blood glucose concentrations in non-diabetic NOD-SCID mice were also significantly lower 3 days after cell implantation (2 Â 10 6 cells: 7.42 ± 0.31 mM, cf. 10.19 ± 0.75 mM before implantation; 5 Â 10 6 cells: 6.91±0.28 mM cf. 10.26±0.40 mM before implantation; Po0.0001 for both comparisons) ( Figure  5a ). In interpreting these findings, it should be noted that control NOD-SCID mice had intrinsically high 'normoglycemic' levels of blood glucose (10.23 ± 0.58 mM) even without STZ administration. These high basal levels were clearly above the threshold of 5 mM for glucose 6 episomal-plasmid cells in diabetic mice promptly reversed hyperglycemia, Po0.0001 and 0.7125 for * cf. ** and * cf. ***, respectively, on day 3. Diabetic mice implanted with 5 Â 10 6 cells were significantly less hyperglycemic than mice implanted with 2 Â 10 6 cells on day 12 (P ¼ 0.0431). The effect began waning after 12 days and the difference was not significant (P ¼ 0.2801) by day 21. Cell implantation in non-diabetic mice also reduced the blood glucose on day 3, P ¼ 0.0015 for # cf. ***. (b) Plasma human insulin levels were significantly higher in diabetic mice implanted with 5 Â 10 6 cells (P ¼ 0.0007, * cf. **). This difference did not persist beyond the 12th day after implantation (P ¼ 0.1087, * cf. ** on day 12). Plasma human insulin concentrations in these mice declined rapidly from day 3 onwards (Po0.0001, day 3 cf. day 7 of **). In contrast, the number of implanted cells did not significantly influence plasma human insulin levels in non-diabetic mice (P ¼ 0.1597, # cf.
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). (c) Glucose tolerance profiles were obtained 1 week post-implantation. AUC values, derived from graphs of blood glucose concentration vs time, were used to evaluate effects on glucose disposal statistically. Diabetic mice implanted with modified cells had significantly improved glucose tolerance, P ¼ 0.0135 and 0.0008 for * cf. ** and * cf. ***, respectively. Glucose tolerance of diabetic mice implanted with 5 Â 10 6 cells was not significantly different from control implanted non-diabetic mice (P ¼ 0.1151). Implantation of episomal-plasmid PBMMSC in non-diabetic mice did not alter glucose tolerance, P ¼ 0.5578 for # cf.
Bone marrow-derived insulin bioimplants NKF Chen et al activation of the EGR1 promoter established from in vitro experiments (Figures 2 and 3) . Thus, circulating human insulin was also detected in these mice, albeit at concentrations 4-to 7-fold lower than that detected in diabetic mice implanted with similar numbers of cells (Figure 5b ). However, glucose tolerance of non-diabetic NOD-SCID mice was unaltered by implantation of modified PBMMSC (Figure 5c ). Taken together, these data from comparably implanted non-diabetic and diabetic mice showed that the EGR1 promoter-insulin construct functioned in an appropriate glucose-sensitive manner in vivo.
Owing to the xenogeneic nature of cell therapy, the foregoing metabolic effects were characteristically shortlived. Compared with the third post-implantation day, hyperglycemia recurred ( Figure 5a ) and plasma human insulin concentrations declined (Figure 5a ) in both celltreated groups 7 days post-implantation. Autopsies showed macroscopic liver necrosis. Histopathological examination revealed features consistent with the activation of an innate immune response provoked by implanting xenogeneic cells in the liver (Supplementary Figure S3) .
Intraperitoneal xenotransplantation. We therefore implanted modified PBMMSC intraperitoneally in an attempt to mitigate rapid stimulation of the innate immune response. Two variables were tested in these experiments. These were (a) the nature of transgenic modification of PBMMSC, that is, whether electroporated with circular plasmid DNA (episomal-plasmid cells) or selected for stable integration of the linearized insulin transgene (stable cells); and (b) cell number.
Independent of all other experimental variables, blood glucose levels of all IP-implanted diabetic mice were significantly lower than diabetic mice implanted with the same number of PBMMSC electroporated without any vector, that is, control implantation (Figure 6a ). Amelioration of hyperglycemia was accompanied by detectable plasma human insulin levels ( Figure 6b ) and significantly improved glucose tolerance (Figure 6c ). Similar, albeit less pronounced, trends were documented in non-diabetic mice implanted with insulin-secreting PBMMSC. Specifically, blood glucose reduction did not exceed 17% (maximal reduction detected: 11.77±0.60 mM before episomal-plasmid-cell-implantation cf. 9.73 ± 0.33 mM 7 days post-implantation) (Figure 6d ). Plasma human insulin concentration was 8.4-fold lower (average plasma human insulin in cell-implanted diabetic mice 3-30 days post-implantation: 181.2 ± 9.5 pM cf. cellimplanted non-diabetic mice: 21.7±2.2 pM) (Figure 6e) . Moreover, glucose tolerance was not altered (P ¼ 0.2228 and 0.7181 for non-diabetic mice implanted with episomal-plasmid and stable cells, respectively, cf. the normal phase of all mice) (Figure 6f ).
The method of cell modification influenced transgenic insulin expression and temporal glycemic trends.
Mice implanted with 5 Â 10 6 episomal-plasmid cells had significantly higher circulating insulin levels than mice implanted with the same number of stable cells on day 7 post-implantation (episomal-plasmid cells: 425.6 pM cf. stable cells: 311.5 pM; P ¼ 0.0003). This result mirrored in vitro data (Figure 4) . Reversal of glycemic improvement and concurrent decline in plasma insulin levels in diabetic mice implanted with episomal-plasmid cells occurred sooner than in diabetic mice implanted with stable cells (Figures 6a and b) . Similar but subtler trends occurred in cell-implanted non-diabetic mice (Figures 6d and e) .
Implantation with higher cell number moderated the decline in therapeutic efficacy. IP implantation of 5 Â 10 6 episomal-plasmid cells was associated with significantly higher plasma human insulin concentrations than implantation of 2 Â 10 6 cells for at least 16 days (plasma human insulin: area under the curve (AUC) days3À16 ¼ 2558 ± 277 (5 Â 10 6 cells) cf. 1664 ± 109 (2 Â 10 6 cells); P ¼ 0.0065) (Figure 6b) , with concomitant reduction in hyperglycemia (Figure 6a) . Similarly, IP implantation of a larger number of stable cells yielded higher concentrations of plasma human insulin ( Figure  6b ) and lower blood glucose levels (Figure 6a ) throughout the observation period. Consistent with these results, the cell-dosing effect was also apparent in glucose tolerance test data (AUC 0À90 ¼ 4587 ± 716 (5 Â 10 6 cells) cf. AUC 0À90 ¼ 6361±508 (2 Â 10 6 cells); P ¼ 0.0487) (Figure 6c ).
Intrahepatic vs intraperitoneal xenotransplantation.
The site of cellular implantation had no significant influence on mean blood glucose concentrations of diabetic mice monitored for 21 days (P ¼ 0.8298) (Figures  5a and 6a) . However, the temporal profiles of glycemic improvement were different. Hyperglycemia was more rapidly corrected in IH-than in IP-implanted mice, that is, significantly lower blood glucose levels 3 days after implantation (14.97 ± 1.15 mM cf. IP-implanted diabetic mice 18.41±0.42 mM; P ¼ 0.0026). This early effect was likely due to prompt vascularization of implanted cells by liver sinusoids and consequently, a higher proportion of early engrafted cells compared with cells placed within the peritoneal cavity. However, this trend was reversed from day 7 onwards such that, by day 21, blood glucose values of IH-implanted diabetic mice had become significantly higher than IP-implanted diabetic mice (IH ¼ 23.70±0.23 mM; IP ¼ 19.96±0.79 mM; P ¼ 0.0313). This was possibly the result of delayed macrophage recruitment into the less vascularized peritoneal compartment. Compared with IP-implanted cells, contact of IH-implanted cells with resident macrophages, for example, Kupffer cells in the recipient liver, may have rendered donor cells more rapidly accessible for destruction. 16 Body weight trends. Concomitant with their improved glycemic status, body weight loss was arrested in all IP-implanted diabetic mice (P ¼ 0.2378, nadir body weight cf. body weight on day 30) (Figure 7a) . In contrast, all IH-implanted and control-implanted diabetic mice continued to lose significant weight over 21 days (Po0.0001).
Ablation of endogenous mouse insulin expression.
Plasma samples from all animals collected on the day of killing were assayed for mouse C-peptide. Plasma mouse C-peptide levels of diabetic mice were 4.22 ± 0.87% of control non-STZ-treated mice, indicating that incomplete ablation and/or regeneration of endogenous b-cells were 
Discussion
We have chosen insulin-deficient diabetes mellitus as a clinical model of interest to investigate the ability of nonvirally modified primary BMMSC to serve as therapeutically meaningful protein-secreting bioimplants. Significant progress has been made in transdifferentiating murine BMMSC into insulin-producing cells. 17 Nonetheless, as the efficiency of such conversion is low, it remains uncertain if clinically meaningful numbers of insulin-producing cells can be generated by this approach. In contrast, recent evidence suggests that genetically modified BMMSC are a promising autologous source for therapy of various diseases. [18] [19] [20] Although non-b-cells may be readily modified to secrete insulin and are likely to resist autoimmune attack, sceptism of their potential clinical utility as functional surrogate b-cells has centered on two deficiencies, namely, weak glucose responsiveness and much slower secretion kinetics by the constitutive pathway. The mean blood glucose concentrations of all IP-implanted diabetic mice were significantly lower than those of control-implanted diabetic mice (Po0.0001). The number of episomal-plasmid cells implanted did not significantly influence glycemic improvement achieved (P ¼ 0.3160, * cf. **). Nonetheless, significantly lower blood glucose levels were recorded in mice implanted with the higher cell number on day 3 post-implantation (P ¼ 0.0388), although this early effect had dissipated by day 12 (P ¼ 0.6115). In contrast, stably modified cells had a more durable therapeutic effect in diabetic mice implanted with the higher cell number (P ¼ 0.0487 on day 30). (b) Mice implanted with more cells had higher plasma human insulin concentrations (P ¼ 0.0291 for * cf. ** and P ¼ 0.0149 for # cf. ## ). For mice implanted with episomal-plasmid cells, cell number difference was significant in the early treatment period, that is, days 3-16 (P ¼ 0.0259) but was not sustained beyond day 16 (P ¼ 0.5290). In contrast, the therapeutic efficacy of implanted stably modified cells was more sustained throughout the experimental period (P ¼ 0.0097 # cf. ## on day 30). Episomal-plasmid cells secreted significantly more human insulin than stably modified cells on day 7 (P ¼ 0.0251). This was reversed from day 12 onwards when stably modified cells secreted more human insulin than episomal-plasmid cells (Po0.0001). (c) Glucose tolerance was tested 1 week postimplantation. All IP-implanted mice had significantly improved glucose tolerance compared with control-implanted diabetic mice (Po0.0001). The mode of cell manipulation did not significantly influence glucose tolerance (P ¼ 0.6173). The effect of cell number was also negligible (P ¼ 0.2178 for * cf. **; P ¼ 0.0678 for # cf.
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). (d) Non-diabetic mice implanted with modified cells had significantly lower blood glucose concentrations on day 7 compared with control-implanted non-diabetic mice (Po0.0001 and P ¼ 0.0291 for * and # , respectively). The lowest blood glucose level recorded exceeded 6 mM. (e) Non-diabetic mice implanted with 5 Â 10 6 episomal-plasmid cells or same number of stably modified cells had similar plasma human insulin concentrations on day 7 (P ¼ 0.9127). Note that levels of human insulin were only 11.2±0.3% (episomal-plasmid cells) and 14.9±0.1% (stably modified cells), compared with diabetic mice implanted with the same number of modified cells. A declining trend of human insulin secretion was also observed, especially in mice implanted with episomal-plasmid cells such that insulin secretion was almost undetectable by day 16. (f) The glucose tolerance of these mice was unaltered (P ¼ 0.4178 for * cf. **; P ¼ 0.7315 for * cf. ***).
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Promoter selection is crucial in driving tightly and rapidly regulated expression of the insulin transgene. Most previous studies have used non-physiological viral promoters, glucose-insensitive promoters or insulinrepressed promoters. 21 Unsurprisingly, these transgenic systems often resulted in one of two extreme outcomes, that is, fatal hypoglycemia or sub-therapeutic insulin expression. In addition, viral promoters are known to undergo early transcriptional silencing. In contrast, use of cell-specific endogenous promoters supports sustained transgene expression. 22, 23 Moreover, several groups have reported that glucose-responsive promoters, such as the insulin and phosphoenolpyruvate kinase promoters, can rapidly evoke transgene expression, that is, within 10-15 min. 24, 25 These findings do not support the view that glucose-dependent transcriptional control is necessarily slow in onset, occurring hours after glucose stimulation.
We report here that the relatively slower kinetics of transcriptionally modulated insulin secretion may be substantially improved by expressing transgenic insulin from a strong constitutive yet glucose-sensitive endogenous promoter. Our data from whole genome transcriptome profiling revealed a subset of glucose-inducible genes that establish BMMSC as a novel class of glucoseresponsive cells. We have selected the human EGR1 promoter from transcriptome data to drive glucoseregulatable insulin expression, as its promoter showed high basal transcriptional activity, and rapid glucose induction and de-induction capacity. EGR1 is an immediate-early gene that is induced by a variety of stimuli within 5-10 min in the absence of de novo protein synthesis. 26 Indeed, the full EGR1 promoter contains multiple response elements and regulatory sites common to many cellular immediate-early gene promoters, 27 and at least six copies of putative carbohydrate-response elements. Binding of EGR1 to other promoters in turn induces the transcription of many downstream genes. 28 Our results are in agreement with recent findings. For instance, several reports showed that EGR1 is rapidly expressed and regulates a cascade of downstream multiple promoters involved in transcribing genes important for glucose homeostasis. 28, 29 Indeed, high glucose upregulates EGR1 expression within minutes. 9 Overexpression of EGR1 activates insulin synthesis in b-cells indirectly by turning on PDX-1 expression, an effect mediated by EGR1 binding to the PDX-1 promoter. EGR1 thus lies upstream of PDX-1 in controlling insulin transcription. 30 Given the rapidity of stimulated insulin gene transcription in b-cells within 20 min by 2-4 mM glucose, 25, 31 it is not surprising that our data showed rapid transgene transcription and secretion by PBMMSC 10-15 min after exposure to high glucose.
Reservations about the somewhat delayed secretory response of modified BMMSC should be considered in light of the known kinetic features of physiological insulin secretion. Biphasic insulin release occurs only under non-physiological conditions, typically during intravenous glucose testing. 32 In fact, the response time of our modified cells to high glucose challenge closely mimics pancreatic response to a mixed meal challenge in normal human subjects. 33 Furthermore, clinically acceptable glycemic control was achieved in diabetic recipients of pancreas allografts or islet transplants despite abnormal insulin secretion kinetics. 34, 35 Indeed, recent data from the NIDDK and JDRF-funded Collaborative Islet Transplant Registry showed that 31-53% of a total of 325 adult recipients of islet transplants suffered severe hypoglycemic episodes. 36 It is worth noting that conventional regimens of insulin injections not infrequently result in peak insulin activity that is mistimed with Figure 7 Body weight trends and endogenous mouse C-peptide levels of NOD-SCID mice. (a) Body weights of all IH-, IP-and control-implanted diabetic mice, and non-diabetic modified cellimplanted and control-implanted mice were pooled for analysis. Body weights at the nadir and on the last experimental day, that is, before the animal was killed, were compared. Both modified celland control-implanted non-diabetic mice were heavier than all other groups on day 30 (Po0.0001). While IP-implanted diabetic mice had a similar mean body weight on day 30 as the mean nadir body weight (P ¼ 0.2378) (that is, indicating arrested weight loss), control-and IH-implanted diabetic mice continued to lose significant weight post-implantation. (b) Plasma mouse C-peptide of all NOD-SCID mice in the study. Plasma samples obtained from all mice before killing were assayed for mouse C-peptide to ascertain the degree of endogenous insulin production. The radioimmunoassay for mouse C-peptide was not crossreactive with human insulin and o0.1% crossreactive with human C-peptide (Linco Research). Both treated and control-implanted diabetic mice had significantly lower levels of plasma mouse C-peptide than nondiabetic controls (Po0.0001 for all comparisons). Treatment of nondiabetic mice was not associated with significant differences in mouse C-peptide levels compared with control untreated nondiabetic mice (P ¼ 0.6741, * cf. **).
Bone marrow-derived insulin bioimplants NKF Chen et al respect to post-prandial glycemia 37 and are thus associated with a known frequency of symptomatic hypoglycemia. 38 This study showed that xenotransplantation of the modified PBMMSC, regardless of the implantation site, promptly and significantly reduced hyperglycemia in diabetic NOD-SCID mice in a cell dose-responsive manner. Notably, non-diabetic mice implanted with the same number of modified cells had slight reductions of blood glucose levels that did not become hypoglycemic (that is, the lowest concentration recorded was 6.4 mM). These in vivo results further strengthen our contention developed from in vitro assays that the EGR1 promoter was indeed sensitive to the physiological range of blood glucose concentrations. Although we showed that physiological and pathological concentrations of insulin and glucocorticoid had no effect on EGR1 promoter activity, studies of longer duration are necessary to ensure that the promoter is only maximally activated by glucose and/or glucose derivatives, without risk of serious or even fatal hypoglycemia.
Xenograft-evoked immune rejection in our study precluded long-term assessment of the performance of transplanted PBMMSC. Although NOD-SCID mice are deficient in T and B lymphoid cells, they retain natural killer cells and the capacity to mount a competent innate immune response by mobilizing monocytes, macrophages and neutrophils. 39 Neutrophils and monocytes activate resident macrophages (such as Kuppfer cells), which rapidly target implanted xenogeneic cells. 40 However, the inability of macrophages to induce cell killing efficiently in the absence of T cells may explain the gradual decline in performance of the implanted PBMMSC. Contrary to the notion that BMMSC have immunosuppressive and immunomodulatory functions in vivo, 41 Prigozhina et al. 42 recently reported that these cells could lose their immunosuppressive potential after allotransplantation. That immune rejection of xenogeneic PBMMSC in this study correlated with recurrent hyperglycemia in diabetic NOD-SCID mice fortuitously supported the essential role of implanted cells in ameliorating insulin deficiency and hyperglycemia achieved earlier.
We noted that direct IH implantation of PBMMSC elicited more rapid immune-mediated destruction of xenogeneic cells compared with intraperitoneal implantation, possibly due to the proximity of intrahepatically implanted cells to resident immune cells in the liver. However, we foresee that autologous implantation would not incur this response. Given reports of fusion of donor bone marrow-derived cells with hepatocytes in recipient organs, 43 implanted BMMSC, may well act as cellular vehicles conveying expression vectors to hepatocytes, thus permitting hepatocyte-mediated protein secretion. Although not performed in this study, tracking the fate of implanted PBMMSC in vivo will be necessary in future work as homing of MSC in vivo is poorly understood. 44 Favorable results reported in this study were due, in part, to the gene delivery method we used. Electroporation is known to increase transgene copy number in the nucleus by several orders of magnitude, thus enhancing expression of the transgene product. 13, 14 Indeed, more insulin was secreted in circular plasmid-electroporated PBMMSC compared with PBMMSC stably modified with the same construct. Cell electroporation offers additional advantages that are especially germane to clinical applications. First, it allows facile ex vivo gene transfer. Second, ex vivo electrotransfer largely eliminates the risks of in vivo dissemination of viral vectors and other potentially toxic polymer-complexed vectors with the attendant risks of adverse immunogenic or genotoxic effects. These risks are not entirely obviated by ex vivo transduction as viral vectors may contaminate transduced cells during in vivo implantation. Third, confirming other published reports, 8, 45 we have shown that electroporation does not lead to genomic integration of circular plasmid DNA and should thus have negligible mutagenic potential. Indeed, non-viral vector is deemed safer than viral vector. 46 However, unlike our previous findings that primary post-mitotic hepatocytes durably retain plasmid vectors and durably express transgenic insulin in vivo, modification with a non-integrating vector system is unlikely to be helpful in BMMSC that have some proliferative capacity in vivo. Recent advances in vector engineering such as the construction of human artificial chromosomes 45 and inclusion of a scaffold matrix attachment region in plasmid DNA for stable episomal retention reportedly achieve durable transgene expression even in the face of active cell proliferation and could be vectors of choice for BMMSC. 22, 47 Notwithstanding the fact that only about half of normal insulin secretion was reconstituted in our study, this level of insulin restoration is clinically meaningful as life-threatening diabetic ketoacidosis is prevented in type I diabetics with merely 10% of physiological circulating insulin. 48 However, it is evident that improvements in reconstituting insulin secretion beyond what we have achieved in this study are needed for a more robust therapeutic effect. This may be achieved by optimizing cell isolation and/or culture protocols that yield therapeutically sufficient cells, gene transfer techniques that yield a larger number of transgene-expressing cells and conditions that enhance cell engraftment. It is worth noting that extremely high transgene expression may be unhelpful because increased protein trafficking from forced overexpression could cause abnormal processing of transgenic proinsulin, leading to endoplasmic reticulum stress and activation of apoptosis.
In conclusion, notwithstanding the challenging conditions attending transplantation of xenogeneic cells into NOD-SCID mice, our data demonstrate that human insulin transgene-transfected PBMMSC were capable of secreting human insulin in response to hyperglycemia, improved the glycemic status of STZ-diabetic mice and did not cause hypoglycemia even in non-diabetic mice. We envisage that implantation of autologous PBMMSC modified with insulin transgene expressed from the EGR1 promoter could provide an in vivo source of quasiphysiological glucose-regulated insulin secretion to restore euglycemia durably in a large animal model of diabetes, for example, STZ-diabetic pigs, as pre-clinical proof of principle before clinical trials.
Materials and methods
Chemicals and reagents
The reagents used and their suppliers are as follows: all reagents for RNA preparations (Sigma-Aldrich, St Louis, 
Animals
Four-to eight-week-old male NOD-SCID mice were housed in specific pathogen-free rooms in the National Cancer Centre and SingHealth Experimental Medicine Centre, Singapore. All mice were exposed to 12-h cycles of light and dark at 18-24 1C. Water and standard rodent chow were provided ad libitum. All animal handling procedures, animal husbandry and experimental protocols were approved by the Institutional Animal Care and Use Committee of the Singapore General Hospital.
Isolation and culture of PBMMSC
See Supplementary Materials and Methods, and Supplementary Figure 1 .
Immuno-characterization of PBMMSC Fluorescence-activated cell sorting analysis. Five million Accutase-detached porcine bone marrowderived cells were resuspended in 60 ml cold staining buffer and 20 ml human FcR blocking reagent (Miltenyi Biotec, Bergisch Gladbach, Germany), and incubated at 4 1C for 15 min. The volume of cell suspension was brought to 500 ml with cold staining buffer. One hundredml was dispensed into each of the five tubes, designated tubes 1-5. Tube 1 served as the unstained control; tube 2 was stained with 10 ml of mouse anti-CD90 conjugated with fluorescein isothiocyanate; tube 3 was stained with 10 ml of isotype control for CD90, that is, fluorescein isothiocyanate-conjugated mouse IgG 1 , k; tube 4 was stained with 10 ml of mouse anti-CD11b conjugated with allophycocyanin (APC); tube 5 was stained with 10 ml of isotype control for CD11b, that is, APC-conjugated mouse IgG 2a , k. CD90 (THY1) and CD11b (ITGAM) were positive and negative markers, respectively, of porcine mesenchymal cells. 49 All antibodies and reagents for fluorescence-activated cell sorting (FACS) analysis were from BD Biosciences, San Diego, CA, USA. All tubes were incubated at 4 1C for 20 min. Tubes 2 and 3 each received additional staining buffer (100 ml). One hundred-ml cell suspension from each of these tubes, that is, tubes 2 and 3, was then transferred to new tubes labeled tubes 6 and 7, respectively, for bivariate staining. To tube 6 was added 10 ml of APC-conjugated mouse anti-CD11b and to tube 7, 10 ml APC-conjugated mouse IgG 2a , k isotype control. These tubes were further incubated for another 20 min at 4 1C. All cells were washed and resuspended in 1 ml cold staining buffer before filtering through 40-mm cell strainers. Flow cytometry was performed on FACSCalibur (BD Biosciences). A total of 10 000 events were acquired for each sample. Data were analyzed and plotted using FlowJo software (Treestar, Ashland, OR, USA). Virtually all cells expressed CD90 (99.80±0.07%) and did not express CD11b (0.08±0.01%) (Supplementary Figure S2) . The latter is a hematopoietic marker expressed by monocytes, granulocytes, natural killer cells and subsets of T and B cells. 50 These cells were not fibroblasts because the latter do not express either of the surface antigens tested. These findings also showed that substantially pure PBMMSC cultures were established using a simple isolation protocol (vide supra). Table 1 ). Cells from each time point were lysed for total RNA isolation; RNA from replicate plates was pooled.
(ii) Target preparation and hybridization. Biotinylated and fragmented cRNA was prepared by the Affymetrix protocol and hybridized to Affymetrix U133 Plus 2.0 Array GeneChip (each time point was profiled in duplicate; there were thus 10 transcriptome data sets). Each array contained probe sets for 39 000 human genes and was scanned in a GeneChip Scanner 3000 (Affymetrix, Santa Clara, CA, USA).
(iii) Data analysis. We normalized signal intensities by global scaling to an arbitrary value of 500 using Microarray Suite software, version 5.0 (Affymetrix). We selected genes whose expression was upregulated and downregulated when HBMMSC were incubated with high and low glucose, respectively. Data were analyzed by the following pairwise comparisons. Selected transcripts were validated by semiquantitative RT-PCR, performed in quadruplicate, using cDNAs hybridized to the arrays. Fold change was calculated by standard DDC t analysis using human HPRT mRNA as internal control. Forward (F) and reverse (R) primers Intraperitoneal implantation. The same number of modified cells in 0.5 ml serum-free StemPro medium was injected into the peritoneal cavity of each mouse. Control animals were implanted with PBMMSC that were electroporated without insulin expression plasmid.
Serial metabolic and biochemical monitoring
Serial body weights and blood glucose concentrations were determined during the experimental period as follows: day À10 (non-diabetic phase), day À5 (diabetic phase after three STZ injections on days À9 to À7), day 0 (day of cell transplantation) and days 3, 7, 12, 16, 21 and 30 post-transplantation. Plasma human insulin concentrations were assayed from day 3 onwards using a human insulin-specific radioimmunoassay. Intraperitoneal glucose tolerance tests were performed on days À10, À5, 7 and 21 as described previously. 4 
Statistical analysis
Data were expressed as mean±s.e.m. Groups were compared using Student's unpaired two-sided t-test (for data with equal variances) or Mann-Whitney U-test (for data with unequal variances). All statistical tests and AUC values were calculated with GraphPad Prism (GraphPad Software, San Diego, CA, USA). Po0.05 was considered to be significant.
